Samuel Chen’s early bet on Zoom Video Communications Inc. made him one of the pandemic economy’s big winners. For his latest act, the little-known Taiwanese billionaire is emerging as a major health-care investor.
His Digital Mobile Venture led a $100 million series D fundraising round this week for biotechnology firm Acepodia after previously investing in the US and Taiwan-based company in 2021.
He’s also accumulated a stake worth about $1.2 billion in anti-cancer therapy firm Polaris Group, which listed in Taiwan last year, and emerged in late 2021 as one of the biggest shareholders in Hong Kong-based Regencell Bioscience Holdings Ltd., according to regulatory filings.
Read the full story on Bloomberg here.